The traditional methodology of identifying genetic mutations in cancer patients often relies on time-consuming processes that destroy precious biopsy samples before a treatment plan can even begin. This fundamental conflict between diagnostic necessity and sample preservation has led to the
The implementation of digital health tools often risks widening the divide between privileged and underserved patient populations, yet recent clinical evidence suggests that standardized remote monitoring may actually be the key to closing these long-standing disparities. The PRO-TECT (AFT-39)
The staggering reality that nearly ninety percent of pharmaceutical candidates fail during clinical trials has forced a fundamental reckoning within the global research community. For many decades, the industry relied almost exclusively on animal models to predict the efficacy and safety of new
Ivan Kairatov is a distinguished figure in the biopharmaceutical industry, possessing a wealth of expertise in research, development, and the integration of innovative technologies into clinical practice. With a career dedicated to understanding the complexities of drug development and the nuances
The quiet disappearance of radiation oncology facilities across the American heartland is carving out vast healthcare voids that fundamentally threaten the survival prospects of millions of rural residents. While aggregate statistics often suggest that the national healthcare infrastructure remains
The persistent challenge of treating metastatic castration-resistant prostate cancer has long centered on the tumor’s ability to remain invisible to the body’s natural immune defenses while resisting standard therapeutic interventions. A groundbreaking preclinical study led by researchers at Weill
